[go: up one dir, main page]

MA56661B1 - Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide - Google Patents

Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide

Info

Publication number
MA56661B1
MA56661B1 MA56661A MA56661A MA56661B1 MA 56661 B1 MA56661 B1 MA 56661B1 MA 56661 A MA56661 A MA 56661A MA 56661 A MA56661 A MA 56661A MA 56661 B1 MA56661 B1 MA 56661B1
Authority
MA
Morocco
Prior art keywords
methyl
methoxyazetidin
dihydropyridin
dioxole
methylthio
Prior art date
Application number
MA56661A
Other languages
English (en)
Inventor
Victor S. Gehling
Alamelu Banda
Original Assignee
Constellation Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals, Inc. filed Critical Constellation Pharmaceuticals, Inc.
Publication of MA56661B1 publication Critical patent/MA56661B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne une forme cristalline 1 de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl)cyclohexyl)-2,4-diméthyl-N-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl)méthyl)benzo[d][1,3]dioxole-5-carboxamide étant utile en tant que modulateurs de l'activité des enzymes modifiant les histones par méthylation. La présente invention concerne également des compositions pharmaceutiquement acceptables comprenant la forme cristalline et les procédés d'utilisation de ces compositions dans le traitement de divers troubles.
MA56661A 2019-07-24 2020-07-23 Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide MA56661B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962878012P 2019-07-24 2019-07-24
EP20754482.6A EP4003532B1 (fr) 2019-07-24 2020-07-23 Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide
PCT/US2020/043178 WO2021016414A1 (fr) 2019-07-24 2020-07-23 Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide

Publications (1)

Publication Number Publication Date
MA56661B1 true MA56661B1 (fr) 2025-01-31

Family

ID=72047059

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56661A MA56661B1 (fr) 2019-07-24 2020-07-23 Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide

Country Status (29)

Country Link
US (1) US12516040B2 (fr)
EP (2) EP4003532B1 (fr)
JP (2) JP7603653B2 (fr)
KR (1) KR20220041129A (fr)
CN (2) CN114450279B (fr)
AU (1) AU2020316073A1 (fr)
BR (1) BR112022001161A2 (fr)
CA (1) CA3148447A1 (fr)
CL (1) CL2022000175A1 (fr)
CO (1) CO2022001482A2 (fr)
DK (1) DK4003532T3 (fr)
ES (1) ES2997972T3 (fr)
FI (1) FI4003532T3 (fr)
HR (1) HRP20241443T1 (fr)
HU (1) HUE069127T2 (fr)
IL (1) IL289972A (fr)
LT (1) LT4003532T (fr)
MA (1) MA56661B1 (fr)
MD (1) MD4003532T2 (fr)
MX (2) MX2022000931A (fr)
MY (1) MY207951A (fr)
PE (1) PE20220562A1 (fr)
PH (1) PH12022550188A1 (fr)
PL (1) PL4003532T3 (fr)
PT (1) PT4003532T (fr)
RS (1) RS66244B1 (fr)
SI (1) SI4003532T1 (fr)
SM (1) SMT202400485T1 (fr)
WO (1) WO2021016414A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3797108B1 (fr) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulateurs de l'enzyme méthyl modifiant, compositions et leur utilisation.
AU2023206700A1 (en) * 2022-01-14 2024-08-29 Dong Wha Pharm. Co., Ltd. 1,3-benzodioxole derivative compound and pharmaceutical composition comprising same
IL317217A (en) 2022-06-13 2025-01-01 Treeline Biosciences Inc BCL6 heterobifunctional 8,1-naphthyridin-2-one joints
AU2023292893A1 (en) 2022-06-13 2025-01-02 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
KR20250036219A (ko) 2022-07-15 2025-03-13 콘스텔레이션 파마슈티칼스, 인크. At-풍부 상호작용 도메인-함유 단백질 1a(arid1a) 돌연변이 암의 치료를 위한 ezh2 억제 요법
CN115403040B (zh) * 2022-08-11 2023-08-01 中国地质大学（北京） 一种可通过光辐射调控导热系数的偶氮苯聚合物表面修饰的金刚石纳米粒子及其制备方法
WO2024038115A1 (fr) 2022-08-17 2024-02-22 Morphosys Ag Thérapie comprenant un anticorps anti-cd19 et des modulateurs d'ezh2
WO2024076663A1 (fr) 2022-10-06 2024-04-11 Constellation Pharmaceuticals, Inc. Thérapies d'inhibition d'ezh2 pour le traitement de cancers à mutation de protéine associée à brca1 (bap1)

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6317850A (ja) 1986-07-11 1988-01-25 Fuji Photo Film Co Ltd ３−フエノキシカテコ−ル類の製造方法
IL92544A0 (en) 1988-12-08 1990-08-31 Duphar Int Res Piperazine derivatives,their preparation and pharmaceutical compositions containing them
JPH02255673A (ja) 1989-03-27 1990-10-16 Fuji Photo Film Co Ltd ４―アリールオキシー１，３―ベンゾジオキソール類およびその製造方法
JPH02255674A (ja) 1989-03-27 1990-10-16 Fuji Photo Film Co Ltd ４―アリールオキシ―１，３―ベンゾジオキソール類およびその製造方法
JPH02269352A (ja) 1989-04-10 1990-11-02 Fuji Photo Film Co Ltd 感光材料
JP2537682B2 (ja) 1989-04-21 1996-09-25 富士写真フイルム株式会社 ３―アリ―ルオキシカテコ―ル類の製造方法
US5296497A (en) 1989-05-16 1994-03-22 Duphar International Research B.V. 3,4-dehydropiperidine derivatives having psychotropic activity
JPH03130280A (ja) 1989-10-17 1991-06-04 Fuji Photo Film Co Ltd ４―アリールオキシ―１，３―ベンゾジオキソール類の製造方法
JP2816492B2 (ja) 1990-05-23 1998-10-27 コニカ株式会社 ハロゲン化銀写真感光材料
JPH0446175A (ja) 1990-06-14 1992-02-17 Fuji Photo Film Co Ltd ５―ヒドロキシ―３，４―メチレンジオキシ安息香酸誘導体の製造法
JPH0641038A (ja) 1992-07-17 1994-02-15 Mitsubishi Kasei Corp カルボン酸誘導体
DE4326151A1 (de) 1993-08-04 1995-02-09 Hoechst Ag Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
US5629200A (en) 1993-11-18 1997-05-13 Daicel Chemical Industries, Ltd. Production of optically active 2-amino-1-phenylethanol derivatives by asymetrical assimilation
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
ATE478672T1 (de) 1996-01-29 2010-09-15 Univ California Methode zur behandlung sexueller fehlfunktionen
HUP9902088A2 (hu) 1996-05-14 2001-04-28 American Home Products Corporation Szubsztituált 1,3-benzodioxol-származékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
US5968929A (en) 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
JPH10287654A (ja) 1997-04-11 1998-10-27 Nissan Chem Ind Ltd ピラゾロン誘導体及び除草剤
PT1026950E (pt) 1997-10-27 2006-06-30 Cortex Pharma Inc Tratamento da esquizofrenia com ampaquinas e neurolepticos
ES2211175T3 (es) 1998-09-29 2004-07-01 Wyeth Holdings Corporation Inhibidores de proteinas de tipo tirosina quinasas a base de 3-cianoquinolinas sustituidas.
EP1384713B1 (fr) 1998-12-23 2008-10-15 SmithKline Beecham Corporation Derives de 4-amino-azepan-3-one comme inhibiteurs de protease
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
MXPA03001332A (es) 2000-08-21 2004-07-08 Astrazeneca Ab Derivados de quinazolina.
AU2001281246A1 (en) 2000-08-23 2002-03-04 The Procter And Gamble Company Benzimidazoles and analogues and their use as neutrophil inhibitors
PT1334091E (pt) 2000-08-24 2013-01-07 Univ Pittsburgh Derivados de tioflavina e seu uso no diagnóstico e terapia da doença de alzheimer
AUPR255401A0 (en) 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
EP1368024A4 (fr) 2001-03-16 2009-03-18 Novogen Res Pty Ltd Traitement de la restenose
WO2002081443A1 (fr) 2001-04-09 2002-10-17 Chiron Corporation Nouveaux composes guanidino
ES2312557T3 (es) 2001-04-19 2009-03-01 Astrazeneca Ab Derivados de quinazolina.
DE10148618B4 (de) 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10148617A1 (de) 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AUPR846401A0 (en) 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
WO2003059258A2 (fr) 2001-12-21 2003-07-24 Cytokinetics, Inc. Compositions et methodes permettant de traiter l'insuffisance cardiaque
WO2003059898A2 (fr) 2002-01-08 2003-07-24 Eisai Co. Ltd. Analogues d'eponemycine et d'epoxomicine et leurs utilisations
CA2473740A1 (fr) 2002-01-18 2003-07-31 David Solow-Cordero Procedes pour traiter des pathologies associees a un recepteur d'edg
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
CN1646119A (zh) 2002-04-09 2005-07-27 诺沃根研究有限公司 涉及异黄－3－烯和异黄烷结构的治疗方法和组合物
DE10219294A1 (de) 2002-04-25 2003-11-13 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
CA2493313C (fr) 2002-07-29 2010-03-09 F. Hoffmann-La Roche Ag Nouveaux benzodioxoles
AU2002951271A0 (en) 2002-09-06 2002-09-19 Novogen Research Pty Ltd Repair of dna mutagenic damage
EP1542654A4 (fr) 2002-09-23 2008-12-17 Novogen Res Pty Ltd Traitement du photovieillissement et de la deterioration actinique de la peau
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
ES2328146T3 (es) 2003-07-28 2009-11-10 Merck Serono Sa 2-imino-4-(tio)oxo-5-policiclovinilazolinas para su uso como inhibidores de p13 quinasas.
US7868205B2 (en) 2003-09-24 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
CA2546643A1 (fr) 2003-11-18 2005-06-02 Novogen Research Pty Ltd Promedicaments a base d'isoflavonoides, compositions de ces promedicaments et procedes therapeutiques les impliquant
WO2005049008A1 (fr) 2003-11-19 2005-06-02 Novogen Research Pty Ltd Compositions et procedes de radiotherapie et de chimiotherapie combinatoires
UA85698C2 (ru) 2004-01-16 2009-02-25 Уайет Хинолиновые промежуточные соединения для синтеза ингибиторов рецепторной тирозинкиназы и способ их получения
AR048528A1 (es) 2004-04-07 2006-05-03 Millennium Pharm Inc Compuestos derivados de quinolina como antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias y composiciones farmacéuticas que los contienen.
US20050245529A1 (en) 2004-04-14 2005-11-03 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
AU2005244736B2 (en) 2004-05-07 2012-06-28 Exelixis Patent Company Llc Raf modulators and methods of use
EP1753428A4 (fr) 2004-05-14 2010-09-15 Abbott Lab Inhibiteurs de kinases en tant qu'agents therapeutiques
ITMI20041347A1 (it) 2004-07-05 2004-10-05 Italfarmaco Spa Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
JP2008515955A (ja) 2004-10-12 2008-05-15 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 貧血の治療のためのＰＩ３キナーゼγ阻害剤
SE0402635D0 (sv) 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
JP2006145294A (ja) 2004-11-17 2006-06-08 Univ Nagoya 蛍光標識を行うラベル化試薬、リガンドを表面にもつ基材の製造方法及びラベル化試薬を用いた測定方法
US7524870B2 (en) 2004-12-03 2009-04-28 Hoffmann-La Roche Inc. Biaryloxymethylarenecarboxylic acids as glycogen synthase activators
DE602006021401D1 (de) 2005-02-28 2011-06-01 Eisai R&D Man Co Ltd Neue kombinierte anwendung einer sulfonamid-verbindung zur behandlung von krebs
WO2006096807A1 (fr) 2005-03-08 2006-09-14 Janssen Pharmaceutica N.V. Dérivés d'acides aminés aza-bicycliques pontés en tant qu'antagonistes de l'intégrine alpha-4
WO2006103449A2 (fr) 2005-03-31 2006-10-05 Astrazeneca Ab Composes
WO2006110447A2 (fr) 2005-04-08 2006-10-19 Bayer Pharmaceuticals Corporation Derives de pyrimidine
PT2444079T (pt) 2005-05-17 2017-03-03 Sarcode Bioscience Inc Composições e métodos para tratamento de distúrbios dos olhos
WO2006127205A2 (fr) 2005-05-25 2006-11-30 Wyeth Procedes de preparation de 3-cyano-quinoleines et intermediaires conçus au moyen de ceux-ci
JPWO2006129609A1 (ja) 2005-05-30 2009-01-08 塩野義製薬株式会社 ２−ナフチルイミノ−５，５−ジ置換−１，３−チアジン誘導体
BRPI0613535A2 (pt) 2005-06-02 2011-01-18 Bayer Cropscience Ag derivados de heteroarila substituìda por fenilalquila
WO2006138418A2 (fr) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Amelioration de la performance cognitive avec des activateurs de sirtuine
NZ565111A (en) 2005-07-15 2011-10-28 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2007014154A2 (fr) 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. Tetracyclines 10-substituees et leurs procedes d'utilisation
EA014495B1 (ru) 2005-08-04 2010-12-30 Янссен Фармацевтика Н.В. Соединения пиримидина в качестве модуляторов серотониновых рецепторов
WO2007020936A1 (fr) 2005-08-17 2007-02-22 Daiichi Sankyo Company, Limited Composé bicyclique hétérocyclique possédant une action fongicide
WO2007081630A2 (fr) 2005-12-21 2007-07-19 Janssen Pharmaceutica, N.V. Inhibiteurs substitues de la pyrimidinyl kinase
CN101007798B (zh) 2006-01-24 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 苯并间二氧杂环戊烯衍生物及其制备方法和医药用途
US8088791B2 (en) 2006-03-23 2012-01-03 Biots Scientific Management Pty Ltd Antibacterial agents
AU2007267174B2 (en) 2006-05-30 2012-08-02 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use
US20100035877A1 (en) 2006-06-26 2010-02-11 Katz David M Methods and compositions for treating pathologies associated with bdnf signaling
WO2008029168A2 (fr) 2006-09-08 2008-03-13 Summit Corporation Plc Traitement de la dystrophie musculaire de duchenne
EP2084141A4 (fr) 2006-10-30 2010-07-21 Novogen Res Pty Ltd Prévention et inversion de la neuropathie périphérique induite par une chimiothérapie
RU2333211C1 (ru) 2006-11-01 2008-09-10 Институт физиологически активных веществ Российской Академии наук N,n`-замещенные 3, 7-диазабицикло[3.3.1]нонаны, обладающие фармакологической активностью, фармацевтические композиции на их основе и способ их применения
NZ580801A (en) 2007-05-10 2012-09-28 Bristol Myers Squibb Co Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
BRPI0704074B8 (pt) 2007-08-29 2021-05-25 Univ Estadual Paulista Julio De Mesquita Filho Unesp derivados piperidínicos da (-)-cassina e (-)-spectalina, composições farmacêuticas contendo os mesmos e processos para sua preparação
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
JP5802127B2 (ja) 2008-04-16 2015-10-28 ポートラ ファーマシューティカルズ， インコーポレイテッド Ｓｙｋ又はｊａｋキナーゼ阻害剤としての２，６−ジアミノ−ピリミジン−５−イル−カルボキサミド類
ES2414159T3 (es) 2008-06-23 2013-07-18 Janssen Pharmaceutica, N.V. Antagonistas de acrilamida piperidilo de CCR2
WO2010019772A2 (fr) 2008-08-14 2010-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oxadiazole-2-oxydes en tant qu'agents antischistosomiaux
JP2010254629A (ja) 2009-04-27 2010-11-11 Bayer Cropscience Ag 光学活性アゾリン誘導体
US9206173B2 (en) 2009-05-28 2015-12-08 Otsuka Pharmaceutical Co., Ltd. Heterocyclic compounds for the treatment of stress-related conditions
AU2010270153A1 (en) 2009-07-10 2012-02-02 Vivalis Substituted pyrrolidinone as inhibitors of hepatitis C NS5B polymerase, the pharmaceutical composition thereof and their therapeutic use
RU2417082C2 (ru) 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
EP2513268B1 (fr) 2009-12-17 2019-02-20 The Lubrizol Corporation Utilisation d'un composé aromatique comme agent anti-usure dans les lubrifinats
BR112012018897A2 (pt) 2010-01-27 2017-10-03 Ab Pharma Ltd Compostos poli-heterocíclicos altamente potentes como inibidores de hcv
CN101851218B (zh) 2010-04-27 2014-10-15 沈阳药科大学 4,5-二取代芳基异硒唑类衍生物及其用途
CN102970869B (zh) 2010-05-07 2014-07-16 葛兰素史密斯克莱有限责任公司 吲哚
EP2580215A4 (fr) 2010-06-10 2014-01-15 Afraxis Holdings Inc 8-(hétérocycyl)pyrido[2,3-d]pyrimidin-7(8h)-ones pour le traitement de troubles du snc
EP2582674B1 (fr) 2010-06-16 2014-10-01 Cymabay Therapeutics, Inc. Agonistes du récepteur gpr120 et leurs utilisations
SI2585469T1 (sl) 2010-06-24 2016-11-30 Leo Pharma A/S Heterociklične spojine benzodioksola ali benzodioksepina kot zaviralci fostodiesteraze
WO2012013725A1 (fr) 2010-07-28 2012-02-02 Medizinische Universität Wien Dérivés de chalcone vinylogue et leur utilisation médicale
US9132136B2 (en) 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
WO2012036278A1 (fr) 2010-09-17 2012-03-22 大正製薬株式会社 Inhibiteur de transporteur de glycine
WO2012045196A1 (fr) 2010-10-09 2012-04-12 Abbott Laboratories Inhibiteurs de la phosphoglycérate kinase
WO2012118812A2 (fr) 2011-02-28 2012-09-07 Epizyme, Inc. Composés hétéroaryles bicycliques substitués condensés en 6,5
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2013025484A1 (fr) 2011-08-12 2013-02-21 Lapchak Paul A Analogues de polyphénol pour traiter une ischémie
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013065835A1 (fr) 2011-11-04 2013-05-10 味の素株式会社 Composition pharmaceutique destinée au traitement du diabète
JP2015504920A (ja) 2012-01-25 2015-02-16 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の製剤
CA2862289C (fr) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulateurs d'enzymes de modification par methylation, leurs compositions et utilisations
WO2013142712A1 (fr) 2012-03-21 2013-09-26 Rutgers, The State University Of New Jersey Agents anti-microbiens
IL308807B2 (en) 2012-04-13 2025-08-01 Epizyme Inc Combination therapy for treating cancer
PL2836491T3 (pl) 2012-04-13 2017-08-31 Epizyme, Inc. Postać soli inhibitora ludzkiej metylotransferazy histonowej EZH2
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
RU2509770C2 (ru) 2012-06-22 2014-03-20 Общество с ограниченной ответственностью "Молекулярные Технологии" Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных
WO2014034898A1 (fr) 2012-08-30 2014-03-06 日本新薬株式会社 Dérivé de pyridine et médicament
CA2900335C (fr) 2012-10-22 2021-10-26 City Of Hope Analogues synthetiques d'epipolythiodioxopiperazines et leurs utilisations
RU2015127822A (ru) 2012-12-13 2017-01-16 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Ингибиторы энхансера гомолога 2 белка zeste
ME02730B (fr) 2013-02-11 2017-10-20 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
MX2015011456A (es) 2013-03-13 2016-05-31 Boston Biomedical Inc Derivados de 3-(arilo o heteroailo) metilenindolino-2-ona como inhibidores de cinasas de la via de las celulas madres cancerosas para el tratamiento del cancer.
US20160108031A1 (en) 2013-04-30 2016-04-21 Heinrich-Heine-Universitat Dusseldorf Inhibitors of nhr2 and/or runx1/eto-tetramerization
KR20150027922A (ko) 2013-09-04 2015-03-13 주식회사 대웅제약 신규한 항진균성 피리디닐하이드라자이드 유도체
ES2828548T3 (es) 2013-09-09 2021-05-26 Youngene Therapeutics Co Ltd Derivado del glucósido C-arilo, método de preparación para el mismo y aplicaciones médicas de este
WO2015069110A1 (fr) 2013-11-07 2015-05-14 Aapa B.V. Multiples a(nta)gonistes de d2/antagonistes de h3 pour le traitement de troubles associés au snc
SMT202000123T1 (it) 2014-03-17 2020-05-08 Daiichi Sankyo Co Ltd Derivati 1,3-benzodiossolici come inibitori di ezh1 e/o di ezh2
GEAP201814347A (en) 2014-06-17 2018-08-10 Pfizer Substituted dihydroisoquinoline compounds
EP3191463B1 (fr) 2014-09-11 2019-10-30 Piramal Enterprises Limited Composés hétérocycliques condensés à titre d'agonistes du gpr120
CA2965729A1 (fr) 2014-10-28 2016-05-06 Glaxosmithkline Intellectual Property (No.2) Limited Inhibiteurs d'ezh2 (enhancer of zeste homolog 2)
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
US20180037568A1 (en) 2015-02-13 2018-02-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
SG10201902664RA (en) 2015-04-20 2019-04-29 Epizyme Inc Combination therapy for treating cancer
BR112018001688B1 (pt) 2015-07-30 2023-05-02 Daiichi Sankyo Company, Limited Uso de um composto
CA2994394A1 (fr) 2015-08-03 2017-02-09 Constellation Pharmaceuticals, Inc. Inhibiteurs d'ezh2 et modulation de la fonction des cellules t regulatrices
WO2017040190A1 (fr) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Formes cristallines de (r)-n-((4-méthoxy-6-méthyl-2-oxo-1,2-dihydropyridin-3-yl)méthyl)-2-méthyl-1-(1-(1-(2,2,2-trifluoroéthyl)pipéridin-4-yl)éthyl)-1h-indole-3-carboxamide
PE20181375A1 (es) 2016-01-13 2018-08-28 Gruenenthal Chemie Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
BR112018015413A2 (pt) 2016-02-09 2018-12-18 Inventisbio Inc inibidores de indoleamina-2,3-dioxigenase (ido)
US20170355708A1 (en) 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
CN106727549A (zh) 2016-11-26 2017-05-31 李�荣 一种治疗抑郁症的药物
CN108314677B (zh) 2017-01-17 2020-06-30 安徽中科拓苒药物科学研究有限公司 一种ezh2抑制剂及其用途
TW201831181A (zh) 2017-01-19 2018-09-01 日商第一三共股份有限公司 用以用於治療ｈｔｌｖ－１相關脊髓病之醫藥組成物
US11466020B2 (en) 2017-03-17 2022-10-11 Cornell University Compounds and compositions for inhibition and elimination of Zika infection and uses for same
KR20200010306A (ko) 2017-05-25 2020-01-30 아락세스 파마 엘엘씨 Kras의 공유적 억제제
EP3700527A4 (fr) 2017-10-25 2021-03-10 Children's Medical Center Corporation Inhibiteurs de papd5 et leurs méthodes d'utilisation
GB201718285D0 (en) 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
JP2021035913A (ja) 2017-12-21 2021-03-04 石原産業株式会社 Ｎ−メトキシアミド化合物又はその塩、及びそれらを含有する農園芸用殺菌剤
JP2021510733A (ja) 2018-01-12 2021-04-30 ケーディーエーシー セラピューティクス，インコーポレーテッドＫｄａｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． がんの処置のための選択的ヒストンデアセチラーゼ３（ｈｄａｃ３）インヒビターと免疫治療剤との組み合わせ
JP2019168611A (ja) 2018-03-23 2019-10-03 株式会社Adeka 光学フィルタ
WO2019191558A1 (fr) 2018-03-30 2019-10-03 San Diego State University (SDSU) Foundation, dba San Diego State University Research Foundation Procédés visant à atténuer et de prévenir les lésions liées à la protéostase
CN111989325B (zh) 2018-04-18 2025-02-25 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
EP3797108B1 (fr) * 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulateurs de l'enzyme méthyl modifiant, compositions et leur utilisation.
KR102689665B1 (ko) 2019-02-19 2024-07-31 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
WO2021016409A1 (fr) 2019-07-24 2021-01-28 Constellation Pharmaceuticals, Inc. Inhibition d'ezh2 dans des polythérapies pour le traitement de cancers

Also Published As

Publication number Publication date
US20220251073A1 (en) 2022-08-11
RS66244B1 (sr) 2024-12-31
PE20220562A1 (es) 2022-04-13
JP7692524B2 (ja) 2025-06-13
JP2022541630A (ja) 2022-09-26
CN118852139A (zh) 2024-10-29
JP7603653B2 (ja) 2024-12-20
CN114450279B (zh) 2024-07-09
MY207951A (en) 2025-03-31
EP4003532A1 (fr) 2022-06-01
SI4003532T1 (sl) 2025-02-28
SMT202400485T1 (it) 2025-01-14
EP4442261A2 (fr) 2024-10-09
AU2020316073A1 (en) 2022-02-17
HRP20241443T1 (hr) 2024-12-20
ES2997972T3 (en) 2025-02-18
BR112022001161A2 (pt) 2022-06-07
LT4003532T (lt) 2024-11-11
WO2021016414A1 (fr) 2021-01-28
EP4003532B1 (fr) 2024-09-04
KR20220041129A (ko) 2022-03-31
CA3148447A1 (fr) 2021-01-28
FI4003532T3 (fi) 2024-12-05
CO2022001482A2 (es) 2022-03-18
CN114450279A (zh) 2022-05-06
PL4003532T3 (pl) 2025-02-03
MX2025004573A (es) 2025-05-02
IL289972A (en) 2022-03-01
PT4003532T (pt) 2024-12-02
JP2025038020A (ja) 2025-03-18
MX2022000931A (es) 2022-05-03
PH12022550188A1 (en) 2022-11-21
US12516040B2 (en) 2026-01-06
EP4442261A3 (fr) 2024-12-11
HUE069127T2 (hu) 2025-02-28
CL2022000175A1 (es) 2022-09-20
MD4003532T2 (ro) 2025-01-31
DK4003532T3 (da) 2024-12-02

Similar Documents

Publication Publication Date Title
MA56661B1 (fr) Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide
MA57825B1 (fr) Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques
BR9712085A (pt) Inibidores de metaloprotease heterocìclicos
HUP0104795A2 (hu) CCR5 modulátor hatású azabicikloalkán vegyületek, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE377011T1 (de) Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer
BR9810841A (pt) Inibidores de metaloprotease alicìclicos
MY138860A (en) Hiv protease inhibitors.
EP1049459A4 (fr) Compositions liquides orales
EA200100992A1 (ru) Ингибиторы фермента impdh
DK0725779T3 (da) Hidtil ukendte (R)-5-Carbamoyl-8-fluor-3-N,N-disubstitueret-amino-3,4-dihydro-2H-1-benzopyraner
ATE234282T1 (de) Polymorphe verbindungen
NO20042964L (no) Spiroazasykliske forbindelser som monoaminreseptormodulatorer
WO2003103603A3 (fr) Nouveau sel de type formiate de o-desmethylvenlafaxine
WO2000002542A3 (fr) Agent a effet antidepressif
MX9207449A (es) Inhibidores de la enzima proteolitica derivada de sacarina.
DK1461318T3 (da) Tetrahydroquinolinanaloge som muscariniske agonister
BR9713178A (pt) Inbidores espirocìclicos da metaloprotease.
SE0202598D0 (sv) Alpha-7 Nicotinic receptor agonists and statins in combination
DK1056454T3 (da) Anvendelse af makrolidforbindelser til behandling af glaukom
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
MA53427B1 (fr) Inhibiteurs de l'arginase et leurs méthodes d'utilisation
EE200200591A (et) Püridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks ühenditeks
MA26732A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
WO2001091796A8 (fr) Methodes, composes et compositions permettant de traiter la goutte
ES2132383T3 (es) Inhibidores de proteasa hiv.